Skip to main content

Advertisement

SpringerLink
Log in

Evolving medical therapies for ulcerative colitis

  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Therapies for patients with ulcerative colitis have, until recently, been limited in scope and efficacy. New formulations of mesalamine and corticosteroids have challenged the older therapies with respect to both efficacy and safety. The application of 6-mercaptopurine and azathioprine for steroid-refractory disease and maintenance of remission has resulted in studies of other candidate immunomodulatory agents. Biologic therapies targeting tumor necrosis factor, adhesion molecules, or other cytokines are under intense scrutiny as potential disease-altering agents that may even replace currently available products. Other approaches, including such wide-ranging products as heparin, nicotine, and probiotics, suggest that control of ulcerative colitis may require an individualized approach for each patient.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading Papers of particular interest, published recently, have been highlighted as: Of importance Of major importance

  1. Levine DS, Riff DS, Pruitt R, et al.: A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002, 97:1398–1407. This study verifies the dose effect of balsalazide as well as providing a direct comparison between balsalazide and mesalamine for the treatment of UC.

    PubMed  CAS  Google Scholar 

  2. Green JR, Mansfield JC, Gibson JA, et al.: A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Aliment Pharmacol Ther 2002, 16:61–68.

    Article  PubMed  CAS  Google Scholar 

  3. Mansfield JC, Giaffer MH, Cann PA, et al.: A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis. Aliment Pharmacol Ther 2002, 16:69–77.

    Article  PubMed  CAS  Google Scholar 

  4. Kruis W, Schreiber S, Theuer D, et al.: Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut 2001, 49:783–789.

    Article  PubMed  CAS  Google Scholar 

  5. Nugent SG, Kumar D, Rampton DS, Evans DF: Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut 2001, 48:571–577.

    Article  PubMed  CAS  Google Scholar 

  6. Hebden JM, Blackshaw PE, Perkins AC, et al.: Limited exposure of the healthy distal colon to orally-dosed formulation is further exaggerated in active left-sided ulcerative colitis. Aliment Pharmacol Ther 2000, 14:155–161. This study evaluates the impact of active colitis upon the colonic release of oral-dosed mesalamine, which may have implications for the various release mechanisms used in mesalamine preparations.

    Article  PubMed  CAS  Google Scholar 

  7. Cohen RD, Woseth DM, Thisted RA, Hanauer SB: A metaanalysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000, 95:1263–1276. This meta-analysis and literature review compares the impact of dose, duration, and method of delivery for commonly used therapies in left-sided UC and proctitis.

    Article  PubMed  CAS  Google Scholar 

  8. Pokrotnieks J, Marlicz K, Paradowski L, et al.: Efficacy and tolerability of mesalazine foam enema (Salofalk foam) for distal ulcerative colitis: a double-blind, randomized, placebo-controlled study. Aliment Pharmacol Ther 2000, 14:1191–1198.

    Article  PubMed  CAS  Google Scholar 

  9. Hanauer S, Good LI, Goodman MW, et al.: Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. Am J Gastroenterol 2000, 95:1749–1754. This trial clearly establishes a maintenance role for topical mesalamine in ulcerative proctitis.

    Article  PubMed  CAS  Google Scholar 

  10. Ardizzone S, Doldo P, Ranzi T, et al.: Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis: a comparative trial vs Salofalk enema. The SAF-3 Study Group. Ital J Gastroenterol Hepatol 1999, 31:677–684.

    PubMed  CAS  Google Scholar 

  11. Malchow H, Gertz B: A new mesalazine foam enema (Claversal Foam) compared with a standard liquid enema in patients with active distal ulcerative colitis. Aliment Pharmacol Ther 2002, 16:415–423.

    Article  PubMed  CAS  Google Scholar 

  12. Safdi M, DeMicco M, Sninsky C, et al.: A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997, 92:1867–1871.

    PubMed  CAS  Google Scholar 

  13. d’Albasio G, Pacini F, Camarri E, et al.: Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol 1997, 92:1143–1147.

    PubMed  CAS  Google Scholar 

  14. Vecchi M, Meucci G, Gionchetti P, et al.: Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study. Aliment Pharmacol Ther 2001, 15:251–256.

    Article  PubMed  CAS  Google Scholar 

  15. Farup PG, Hinterleitner TA, Lukas M, et al.: Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflamm Bowel Dis 2001, 7:237–242.

    Article  PubMed  CAS  Google Scholar 

  16. Hussain FN, Ajjan RA, Kapur K, et al.: Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. Aliment Pharmacol Ther 2001, 15:53–62.

    Article  PubMed  CAS  Google Scholar 

  17. Kane SV, Cohen RD, Aikens JE, Hanauer SB: Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001, 96:2929–2933. This novel study reveals rates and risk factors for nonadherence to prescribed mesalamine, raising awareness of a potential reason for "failure" of previously successful therapy.

    Article  PubMed  CAS  Google Scholar 

  18. Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al.: The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001, 121:255–260. This study quantifies the use and success of corticosteroids in IBD and exemplifies the need for alternatives to steroids in these patients.

    Article  PubMed  CAS  Google Scholar 

  19. Rufle W, Fruhmorgen P, Huber W, Kimmig JM: Budesonide foam as a new therapeutic principle in distal ulcerative colitis in comparison with mesalazine enema: an open, controlled, randomized and prospective multicenter pilot study. Z Gastroenterol 2000, 38:287–293.

    Article  PubMed  CAS  Google Scholar 

  20. Nos P, Hinojosa J, Gomollon F, Ponce J: Budesonide in inflammatory bowel disease: a meta-analysis. Med Clin (Barc) 2001, 116:47–53.

    CAS  Google Scholar 

  21. Sambuelli A, Boerr L, Negreira S, et al.: Budesonide enema in pouchitis: a double-blind, double-dummy, controlled trial. Aliment Pharmacol Ther 2002, 16:27–34.

    Article  PubMed  CAS  Google Scholar 

  22. Rodriguez M, Antunez JA, Taboada C, et al.: Colon-specific delivery of budesonide from microencapsulated cellulosic cores: evaluation of the efficacy against colonic inflammation in rats. J Pharm Pharmacol 2001, 53:1207–1215.

    Article  PubMed  CAS  Google Scholar 

  23. Nolen H III, Fedorak RN, Friend DR: Budesonide-beta-Dglucuronide: a potential prodrug for treatment of ulcerative colitis. J Pharm Sci 1995, 84:677–681.

    Article  PubMed  CAS  Google Scholar 

  24. Rizzello F, Gionchetti P, D’Arienzo A, et al.: Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2002, 16:1109–1116.

    Article  PubMed  CAS  Google Scholar 

  25. Sood A, Midha V, Sood N, et al.: Methylprednisolone acetate versus oral prednisolone in moderately active ulcerative colitis. Indian J Gastroenterol 2002, 21:11–13.

    PubMed  CAS  Google Scholar 

  26. Mahadevan U, Tremaine WJ, Johnson T, et al.: Intravenous azathioprine in severe ulcerative colitis: a pilot study. Am J Gastroenterol 2000, 95:3463–3468.

    Article  PubMed  CAS  Google Scholar 

  27. Sood A, Kaushal V, Midha V, et al.: The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis. J Gastroenterol 2002, 37:270–274.

    Article  PubMed  CAS  Google Scholar 

  28. Campbell S, Ghosh S: Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-aminosalicylate therapy. Eur J Gastroenterol Hepatol 2001, 13:1297–1301.

    Article  PubMed  CAS  Google Scholar 

  29. Mate-Jimenez J, Hermida C, Cantero-Perona J, Moreno-Otero R: 6-Mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000, 12:1227–1233.

    PubMed  CAS  Google Scholar 

  30. Cohen RD, Stein R, Hanauer SB: Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999, 94:1587–1592. Comprehensive open-label evaluation of the initial success of cyclosporine and the need for long-term maintenance therapy with 6-MP.

    Article  PubMed  CAS  Google Scholar 

  31. Actis GC, Bresso F, Astegiano M, et al.: Safety and efficacy of azathioprine in the maintenance of ciclosporin-induced remission of ulcerative colitis. Aliment Pharmacol Ther 2001, 15:1307–1311.

    Article  PubMed  CAS  Google Scholar 

  32. Fraser AG, Orchard TR, Jewell DP: The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002, 50:485–489.

    Article  PubMed  CAS  Google Scholar 

  33. Martinez F, Nos P, Pastor M, et al.: Adverse effects of azathioprine in the treatment of inflammatory bowel disease. Rev Esp Enferm Dig 2001, 93:769–778.

    PubMed  CAS  Google Scholar 

  34. Bowen DG, Selby WS: Use of 6-mercaptopurine in patients with inflammatory bowel disease previously intolerant of azathioprine. Dig Dis Sci 2000, 45:1810–1813.

    Article  PubMed  CAS  Google Scholar 

  35. Boulton-Jones JR, Pritchard K, Mahmoud AA: The use of 6-mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy. Aliment Pharmacol Ther 2000, 14:1561–1565.

    Article  PubMed  CAS  Google Scholar 

  36. Orth T, Peters M, Schlaak JF, et al.: Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study. Am J Gastroenterol 2000, 95:1201–1207. See annotation for [37].

    Article  PubMed  CAS  Google Scholar 

  37. Fellermann K, Steffen M, Stein J, et al.: Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease. Aliment Pharmacol Ther 2000, 14:171–176. Both of these studies analyze the use of MMF in UC, revealing that it is less efficacious than AZA and unlikely to provide long-term remission in steroid-dependent patients.

    Article  PubMed  CAS  Google Scholar 

  38. Skelly MM, Logan RF, Jenkins D, et al.: Toxicity of mycophenolate mofetil in patients with inflammatory bowel disease. Inflamm Bowel Dis 2002, 8:93–97.

    Article  PubMed  Google Scholar 

  39. Lichtiger S, Present DH, Kornbluth A, et al.: Cyclosporin in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994, 330:1841–1845.

    Article  PubMed  CAS  Google Scholar 

  40. Hyde GM, Jewell DP, Kettlewell MG, Mortensen NJ: Cyclosporin for severe ulcerative colitis does not increase the rate of perioperative complications. Dis Colon Rectum 2001, 44:1436–1440.

    Article  PubMed  CAS  Google Scholar 

  41. Navazo L, Salata H, Morales S, et al.: Oral microemulsion cyclosporine in the treatment of steroid-refractory attacks of ulcerative and indeterminate colitis. Scand J Gastroenterol 2001, 36:610–614.

    Article  PubMed  CAS  Google Scholar 

  42. Bousvaros A, Kirschner BS, Werlin SL, et al.: Oral tacrolimus treatment of severe colitis in children. J Pediatr 2000, 137:794–799.

    Article  PubMed  CAS  Google Scholar 

  43. Vandell AG, DiPiro JT: Low-dosage methotrexate for treatment and maintenance of remission in patients with inflammatory bowel disease. Pharmacotherapy 2002, 22:613–620.

    Article  PubMed  CAS  Google Scholar 

  44. Fraser AG, Morton D, McGovern D, et al.: The efficacy of methotrexate for maintaining remission in inflammatory bowel disease. Aliment Pharmacol Ther 2002, 16:693–697.

    Article  PubMed  CAS  Google Scholar 

  45. Sands BE, Tremaine WJ, Sandborn WJ, et al.: Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001, 7:83–88.

    Article  PubMed  CAS  Google Scholar 

  46. Chey WY, Hussain A, Ryan C, et al.: Infliximab for refractory ulcerative colitis. Am J Gastroenterol 2001, 96:2373–2381.

    Article  PubMed  CAS  Google Scholar 

  47. Present DH: Infliximab therapy for ulcerative colitis: many unanswered questions. Am J Gastroenterol 2001, 96:2294–2296.

    Article  PubMed  CAS  Google Scholar 

  48. Chey WY: Infliximab for patients with refractory ulcerative colitis. Inflamm Bowel Dis 2001, 7(Suppl-1):S30-S33.

    Article  PubMed  Google Scholar 

  49. Kaser A, Mairinger T, Vogel W, Tilg H: Infliximab in severe steroid-refractory ulcerative colitis: a pilot study. Wien Klin Wochenschr 2001, 113:930–933.

    PubMed  CAS  Google Scholar 

  50. Mamula P, Markowitz JE, Brown KA, et al.: Infliximab as a novel therapy for pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr 2002, 34:307–311.

    Article  PubMed  CAS  Google Scholar 

  51. Serrano MS, Schmidt-Sommerfeld E, Kilbaugh TJ, et al.: Use of infliximab in pediatric patients with inflammatory bowel disease. Ann Pharmacother 2001, 35:823–828.

    Article  PubMed  CAS  Google Scholar 

  52. Madsen SM, Schlichting P, Davidsen B, et al.: An open-labeled, randomized study comparing systemic interferon-alpha-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis. Am J Gastroenterol 2001, 96:1807–1815.

    PubMed  CAS  Google Scholar 

  53. Maev IV, Grigorian SS, Gadzhieva MG, et al.: Interferon status of patients with non-specific ulcerous colitis and its correction with interferon inducers. Ter Arkh 2002, 74:31–35.

    PubMed  CAS  Google Scholar 

  54. Gordon FH, Hamilton MI, Donoghue S, et al.: A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther 2002, 16:699–705.

    Article  PubMed  CAS  Google Scholar 

  55. Feagan BG, McDonald JWD, Greenberg G, et al.: An ascending dose trial of a humanized A4B7 antibody in ulcerative colitis (UC). Gastroenterology 2000, 118:A874.

    Article  Google Scholar 

  56. Mantzaris GJ, Petraki K, Archavlis E, et al.: A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand J Gastroenterol 2001, 36:971–974.

    Article  PubMed  CAS  Google Scholar 

  57. Parlak E, Dagli U, Ulker A, et al.: Comparison of 5-amino salicylic acid plus glucocorticosteroid with metronidazole and ciprofloxacin in patients with active ulcerative colitis. J Clin Gastroenterol 2001, 33:85–86.

    Article  PubMed  CAS  Google Scholar 

  58. Ang YS, Mahmud N, White B, et al.: Randomized comparison of unfractionated heparin with corticosteroids in severe active inflammatory bowel disease. Aliment Pharmacol Ther 2000, 14:1015–1022.

    Article  PubMed  CAS  Google Scholar 

  59. Panes J, Esteve M, Cabre E, et al.: Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis. Gastroenterology 2000, 119:903–908.

    Article  PubMed  CAS  Google Scholar 

  60. Dotan I, Hallak A, Arber N, et al.: Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: an open trial. Dig Dis Sci 2001, 46:2239–2244.

    Article  PubMed  CAS  Google Scholar 

  61. Vrij AA, Jansen JM, Schoon EJ, et al.: Low molecular weight heparin treatment in steroid refractory ulcerative colitis: clinical outcome and influence on mucosal capillary thrombi. Scand J Gastroenterol 2001, 234 (Suppl):41–47.

    Article  Google Scholar 

  62. Odes HS, Fich A, Reif S, et al.: Effects of current cigarette smoking on clinical course of Crohn’s disease and ulcerative colitis. Dig Dis Sci 2001, 46:1717–1721.

    Article  PubMed  CAS  Google Scholar 

  63. Guslandi M: Long-term effects of a single course of nicotine treatment in acute ulcerative colitis: remission maintenance in a 12-month follow-up study. Int J Colorectal Dis 1999, 14:261–262.

    Article  PubMed  CAS  Google Scholar 

  64. Guslandi M, Frego R, Viale E, Testoni PA: Distal ulcerative colitis refractory to rectal mesalamine: role of transdermal nicotine versus oral mesalamine. Can J Gastroenterol 2002, 16:293–296.

    PubMed  Google Scholar 

  65. Cohen RD, Hanauer SB: Nicotine in ulcerative colitis: How does it work and how can we use it? Clin Immunother 1996, 5:169–174.

    Google Scholar 

  66. Lewis JD, Lichtenstein GR, Stein RB, et al.: An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis. Am J Gastroenterol 2001, 96:3323–3328.

    PubMed  CAS  Google Scholar 

  67. Jarnerot G, Strom M, Danielsson A, et al.: Allopurinol in addition to 5-aminosalicylic acid based drugs for the maintenance treatment of ulcerative colitis. Aliment Pharmacol Ther 2000, 14:1159–1162.

    Article  PubMed  CAS  Google Scholar 

  68. Joelsson M, Andersson M, Bark T, et al.: Allopurinol as prophylaxis against pouchitis following ileal pouch-anal anastomosis for ulcerative colitis: a randomized placebo-controlled double-blind study. Scand J Gastroenterol 2001, 36:1179–1184.

    Article  PubMed  CAS  Google Scholar 

  69. Bariol C, Meagher AP, Vickers CR, et al.: Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. J Gastroenterol Hepatol 2002, 17:135–139.

    Article  PubMed  CAS  Google Scholar 

  70. van Bergeijk JD, Wilson JH, Nielsen OH, et al.: Octreotide in patients with active ulcerative colitis treated with high dose corticosteroids (OPUS 1). Eur J Gastroenterol Hepatol 2002, 14:243–248.

    Article  PubMed  Google Scholar 

  71. Middleton SJ, Naylor S, Woolner J, Hunter JO: A double-blind, randomized, placebo-controlled trial of essential fatty acid supplementation in the maintenance of remission of ulcerative colitis. Aliment Pharmacol Ther 2002, 16:1131–1135.

    Article  PubMed  CAS  Google Scholar 

  72. Ben-Arye E, Goldin E, Wengrower D, et al.: Wheat grass juice in the treatment of active distal ulcerative colitis: a randomized double-blind placebo-controlled trial. Scand J Gastroenterol 2002, 37:444–449.

    Article  PubMed  CAS  Google Scholar 

  73. Rembacken BJ, Snelling AM, Hawkey PM, et al.: Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999, 354:635–639.

    Article  PubMed  CAS  Google Scholar 

  74. Gionchetti P, Rizzello F, Venturi A, et al.: Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000, 119:305–309. The first placebo-controlled, randomized trial showing therapeutic use of a probiotic cocktail for prevention of relapse in chronic relapsing pouchitis.

    Article  PubMed  CAS  Google Scholar 

  75. Heuschkel R, Afzal N, Wuerth A, et al.: Complementary medicine use in children and young adults with inflammatory bowel disease. Am J Gastroenterol 2002, 97:382–388.

    Article  PubMed  Google Scholar 

  76. Yang C, Yan H: Observation of the efficacy of acupuncture and moxibustion in 62 cases of chronic colitis. J Tradit Chin Med 1999, 19:111–114.

    PubMed  CAS  Google Scholar 

  77. Chen Q, Zhang H: Clinical study on 118 cases of ulcerative colitis treated by integration of traditional Chinese and Western medicine. J Tradit Chin Med 1999, 19:163–165.

    PubMed  CAS  Google Scholar 

  78. Langmead L, Dawson C, Hawkins C, et al.: Antioxidant effects of herbal therapies used by patients with inflammatory bowel disease: an in vitro study. Aliment Pharmacol Ther 2002, 16:197–205.

    Article  PubMed  CAS  Google Scholar 

  79. Tytgat GN, Van Nueten L, Van De Velde I, et al.: Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studies. Aliment Pharmacol Ther 2002, 16:87–99.

    Article  PubMed  CAS  Google Scholar 

  80. Auwerda JJ, Zijlstra FJ, Tak CJ, et al.: Ridogrel enemas in distal ulcerative colitis. Eur J Gastroenterol Hepatol 2001, 13:397–400.

    Article  PubMed  CAS  Google Scholar 

  81. Kono T, Nomura M, Kasai S, Kohgo Y: Effect of ecabet sodium enema on mildly to moderately active ulcerative proctosigmoiditis: an open-label study. Am J Gastroenterol 2001, 96:793–797.

    Article  PubMed  CAS  Google Scholar 

  82. Vernia P, Monteleone G, Grandinetti G, et al.: Combined oral sodium butyrate and mesalazine treatment compared to oral mesalazine alone in ulcerative colitis: randomized, doubleblind, placebo-controlled pilot study. Dig Dis Sci 2000, 45:976–981.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Section of Gastroenterology, University of Chicago Medical Center, MC 4076, 5841 South Maryland Avenue, 60637, Chicago, IL, USA

    Russell D. Cohen MD

Authors
  1. Russell D. Cohen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cohen, R.D. Evolving medical therapies for ulcerative colitis. Curr Gastroenterol Rep 4, 497–505 (2002). https://doi.org/10.1007/s11894-002-0026-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-002-0026-y

Keywords

Search

Navigation